FDA allows Houston cancer doctor to resume drug trial
Por um escritor misterioso
Descrição
Federal regulators have lifted a partial hold on a clinical trial performed by Stanislaw
Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study - The Lancet Oncology
New Drugs for Ovarian Cancer Patients - WSJ
Harnessing the Immune System to Fight Cancer - The New York Times
Doctor claims to cure pediatric cancer, critics skeptical
Early drug development in solid tumours: analysis of National Cancer Institute-sponsored phase 1 trials - The Lancet
/archive-images.prod.global.a201836.reutersmedia.net/2016/10/08/LYNXNPEC9706G.JPG)
Novartis challenges Pfizer with strong breast cancer drug data
At the Bedside: New focal therapies at UTHealth Houston make prostate cancer treatment easier on patients - UTHealth News - UTHealth Houston
Drug factory' implants eliminate ovarian, colorectal cancer in mice, Rice News, News and Media Relations
New drug appears to cure rectal cancer in 100% of patients in clinical trial
FDA approves first gene-editing treatment for human illness
In the compelling follow-up to the internationally award-winning documentary, Burzynski, the Movie; Burzynski: Cancer is Serious Business, Part II
Burzynski: Cancer Is Serious Business Part II
FDA panel: Benefit of 'highly anticipated' lung cancer drug can't be interpreted reliably
Brian_Wice
de
por adulto (o preço varia de acordo com o tamanho do grupo)
